<DOC>
	<DOCNO>NCT01307436</DOCNO>
	<brief_summary>The primary purpose study ass whether protection afford Epaxal vaccine co-administered diphtheria , tetanus , Bordetella pertussis , Haemophilus influenzae type b , inactivated polio vaccine ( DTPaHibIPV ) , oral polio vaccine ( OPV ) ( measles mumps rubella ) MMR vaccine hepatitis A inferior protection afford Epaxal administer alone . The aim follow-up phase obtain information long term protection afford Epaxal , compare alternative hepatitis A vaccine ( Havrix ) .</brief_summary>
	<brief_title>Long Term Follow-up Study Assess Safety Immunogenicity Hepatitis A Vaccine Administered With Absence DTPaHibIPV , OPV MMR Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Original study : Written inform consent obtain parent/legal guardian subject . Free obvious health problem establish medical history and/or clinical examination enter study . At least 8 kg body weight age 12 month . Followup phase : Subjects enrol randomise original study receive two dos hepatitis A study vaccine . Original study : Children receive 3 documented dos DTPaHib polio vaccine infancy Children receive document dose MMR infancy Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period 30 day safety followup last dose . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration systemic corticosteroid ( inhaled topical steroid allow ) . Administration vaccine foreseen study protocol within 4 week prior first dose study vaccine . Previous vaccination hepatitis A . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness Acute disease time enrolment . Followup phase : Children receive hepatitis A antigen contain vaccine since last visit</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis A Vaccine</keyword>
	<keyword>Combined Vaccines</keyword>
	<keyword>DTP Vaccine</keyword>
	<keyword>MMR Vaccine</keyword>
</DOC>